Contineum Therapeutics, Inc. (CTNM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Contineum Therapeutics reported revenue of $0. Net income was -$60.0M, or -$2.17 per diluted share. Operating activities generated -$55.3M of cash, leaving -$55.5M of free cash flow. At fiscal year end, Contineum Therapeutics held $276.6M in total assets against $15.7M in total liabilities, including $75.6M of cash and equivalents.
Open the full interactive Contineum Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Contineum Therapeutics Key Stats
| Share Price | $8.42 |
|---|---|
| Market Cap | $315.5M |
| 52-Week Range | $8.42 – $17.57 |
| Shares Outstanding | 37.5 million (basic, 2026 Q2) |
Contineum Therapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$50.9M | -$68.1M |
| Pre-Tax Income | -$42.3M | -$60.1M |
| Income Tax | $0 | $0 |
| Net Income | -$42.3M | -$60.0M |
| Diluted EPS | -$2.18 | -$2.17 |
Contineum Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$12.8M | -$15.2M | -$14.5M | -$15.2M |
| Diluted EPS | — | -$0.55 | -$0.39 | -$0.40 |
Contineum Therapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $21.9M | $75.6M |
| Current Assets | $206.4M | $267.9M |
| Total Assets | $212.8M | $276.6M |
| Current Liabilities | $10.0M | $9.7M |
| Total Liabilities | $14.8M | $15.7M |
| Shareholders' Equity | $198.1M | $261.0M |
Contineum Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$32.8M | -$55.3M |
| Cash From Investing | -$69.7M | -$3.7M |
| Cash From Financing | $109.0M | $112.7M |
| Free Cash Flow | -$33.4M | -$55.5M |
Figures from Contineum Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Contineum Therapeutics financials page for every line item.
Contineum Therapeutics Company Profile
| Ticker | CTNM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001855175 |
Frequently Asked Questions
What was Contineum Therapeutics' revenue in fiscal 2025?
Contineum Therapeutics (CTNM) reported revenue of $0 for fiscal 2025.
What was Contineum Therapeutics' net income in fiscal 2025?
Contineum Therapeutics reported net income of -$60.0M for fiscal 2025.
What was Contineum Therapeutics' earnings per share (EPS) in fiscal 2025?
Contineum Therapeutics' diluted EPS was -$2.17 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Contineum Therapeutics generate in fiscal 2025?
Contineum Therapeutics generated -$55.5M of free cash flow in fiscal 2025.
What was Contineum Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Contineum Therapeutics reported revenue of $0.
How many shares of Contineum Therapeutics are outstanding?
Contineum Therapeutics reported a weighted average of 37.5 million basic shares outstanding in 2026 Q2.
What is Contineum Therapeutics' market cap?
Based on its latest closing price, Contineum Therapeutics (CTNM) has a market capitalization of about $315.5M.
When does Contineum Therapeutics' fiscal year end?
Contineum Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Contineum Therapeutics headquartered?
Contineum Therapeutics lists its business address in San Diego, California in its SEC filings.